Phase II Study With Cabozantinib in Patients With RET Positive NSCLC (CRETA) | EXEL Message Board Posts

EXEL   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  22946 of 23128  at  10/18/2019 11:22:46 PM  by

wilderguide


 In response to msg 22945 by  Pacific
view thread

Re: Phase II Study With Cabozantinib in Patients With RET Positive NSCLC (CRETA)

It's true...what they say....
You can't gallop any faster than the horse you are riding. But the startup of this trial begs the question, "Why now?"
The NCCN has had a Category 2a listing for cabozantinib for some ~3 years in RET-driven NSCLC. The topic of this NSCLC trial structure and biometrics has been discussed ad nauseum by members of this board dating back at least 3 years, and EXEL management has been chastised at length for omitting the development of Cabo in the lung space. What gives?
What has changed? Why did this take so long?


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 3     Views: 297
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
22947 Re: Phase II Study With Cabozantinib in Patients With RET Positive NSCLC (CRETA) erniewerner 2 10/19/2019 7:50:11 AM


About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...